Allergan Clashes With Buyers Over Cert. Bid In Antitrust MDL
A group of direct Allergan buyers seeking to pursue a class action over a delayed rollout of a cheaper generic version of the drugmaker's dry-eye medication Restasis traded barbs with the company Tuesday over how...To view the full article, register now.
Already a subscriber? Click here to view full article